Global Information
회사소개 | 문의 | 비교리스트

성불편증 : 역학 인사이트(-2030년)

Gender dysphoria - Epidemiology Insight - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 11월 상품 코드 966780
페이지 정보 영문 60 Pages
가격
US $ 3,750 ₩ 4,191,000 PDF (Single User License)
US $ 7,500 ₩ 8,382,000 PDF (Site License)
US $ 11,250 ₩ 12,574,000 PDF (Global License)


성불편증 : 역학 인사이트(-2030년) Gender dysphoria - Epidemiology Insight - 2030
발행일 : 2020년 11월 페이지 정보 : 영문 60 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 성불편증(Gender dysphoria) 역학과 관련 시장에 대해 조사한 것으로, 질환의 배경과 개요, 역학과 환자수, 현재의 치료법, KOL(Key Opinion Leadaer)의 견해, 충족되지 않은 욕구 등의 정보를 제공합니다.

목차

제1장 주요 조사 결과

제2장 개요

제3장 질환의 배경과 개요

  • 서론
  • 징후와 증상
  • 병태생리학
  • 위험인자
  • 진단

제4장 환자 치료 과정

제5장 역학과 환자수

  • 주요 조사 결과
  • 전제조건과 근거 : 주요 7개국
  • 역학 시나리오 : 주요 7개국
    • 주요 7개국의 역학 시나리오
  • 미국
  • 유럽 5개국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본

제6장 치료 알고리즘, 현재의 치료와 의료

  • 치료와 관리
  • 치료 알고리즘

제7장 KOL(Key Opinion Leadaer)의 견해

제8장 충족되지 않은 욕구

제9장 부록

  • 참고 문헌
  • 보고서의 조사 방법

제10장 DelveInsight의 서비스 내용

제11장 면책사항

제12장 DelveInsight에 대해

LSH 20.11.04

List of Tables

  • Table 1: Summary of Gender Dysphoria Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: DSM-IV versus DSM-5 diagnostic criteria
  • Table 3: Prevalent Population of Gender Dysphoria in 7MM (2017-2030)
  • Table 4: Prevalence of Gender Dysphoria in the United States (2017-2030)
  • Table 5: Gender-specific Prevalence of Gender Dysphoria in the United States (2017-2030)
  • Table 6: Comorbidities Associated with Gender Dysphoria in the United States (2017-2030)
  • Table 7: Prevalence of Gender Dysphoria in Germany (2017-2030)
  • Table 8: Gender-specific Prevalence of Gender Dysphoria in Germany (2017-2030)
  • Table 9: Comorbidities Associated with Gender Dysphoria in Germany (2017-2030)
  • Table 10: Prevalence of Gender Dysphoria in France (2017-2030)
  • Table 11: Gender-specific Prevalence of Gender Dysphoria in France (2017-2030)
  • Table 12: Comorbidities Associated with Gender Dysphoria in France (2017-2030)
  • Table 13: Prevalence of Gender Dysphoria in Italy (2017-2030)
  • Table 14: Gender-specific Prevalence of Gender Dysphoria in Italy (2017-2030)
  • Table 15: Comorbidities Associated with Gender Dysphoria in Italy (2017-2030)
  • Table 16: Prevalence of Gender Dysphoria in Spain (2017-2030)
  • Table 17: Gender-specific Prevalence of Gender Dysphoria in Spain (2017-2030)
  • Table 18: Comorbidities Associated with Gender Dysphoria in Spain (2017-2030)
  • Table 19: Prevalence of Gender Dysphoria in the United Kingdom (2017-2030)
  • Table 20: Gender-specific Prevalence of Gender Dysphoria in the United Kingdom (2017-2030)
  • Table 21: Comorbidities Associated with Gender Dysphoria in the United Kingdom (2017-2030)
  • Table 22: Prevalence of Gender Dysphoria in Japan (2017-2030)
  • Table 23: Gender-specific Prevalence of Gender Dysphoria in Japan (2017-2030)
  • Table 24: Comorbidities Associated with Gender Dysphoria in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Etiology of Gender Dysphoria
  • Figure 3: Prevalent Population of Gender Dysphoria in 7MM (2017-2030)
  • Figure 4: Prevalence of Gender Dysphoria in the United States (2017-2030)
  • Figure 5: Gender-specific Prevalence of Gender Dysphoria in the United States (2017-2030)
  • Figure 6: Comorbidities Associated with Gender Dysphoria in the United States (2017-2030)
  • Figure 7: Prevalence of Gender Dysphoria in Germany (2017-2030)
  • Figure 8: Gender-specific Prevalence of Gender Dysphoria in Germany (2017-2030)
  • Figure 9: Comorbidities Associated with Gender Dysphoria in Germany (2017-2030)
  • Figure 10: Prevalence of Gender Dysphoria in France (2017-2030)
  • Figure 11: Gender-specific Prevalence of Gender Dysphoria in France (2017-2030)
  • Figure 12: Comorbidities Associated with Gender Dysphoria in France (2017-2030)
  • Figure 13: Prevalence of Gender Dysphoria in Italy (2017-2030)
  • Figure 14: Gender-specific Prevalence of Gender Dysphoria in Italy (2017-2030)
  • Figure 15: Comorbidities Associated with Gender Dysphoria in Italy (2017-2030)
  • Figure 16: Prevalence of Gender Dysphoria in Spain (2017-2030)
  • Figure 17: Gender-specific Prevalence of Gender Dysphoria in Spain (2017-2030)
  • Figure 18: Comorbidities Associated with Gender Dysphoria in Spain (2017-2030)
  • Figure 19: Prevalence of Gender Dysphoria in the United Kingdom (2017-2030)
  • Figure 20: Gender-specific Prevalence of Gender Dysphoria in the United Kingdom (2017-2030)
  • Figure 21: Comorbidities Associated with Gender Dysphoria in the United Kingdom (2017-2030)
  • Figure 22: Prevalence of Gender Dysphoria in Japan (2017-2030)
  • Figure 23: Gender-specific Prevalence of Gender Dysphoria in Japan (2017-2030)
  • Figure 24: Comorbidities Associated with Gender Dysphoria in Japan (2017-2030)
  • Figure 25: Male-to-female gender-affirmation surgical options
  • Figure 26: Female-to-male gender-affirmation surgical options
  • Figure 27: Female to male patient journey for Gender Dysphoria
  • Figure 28: Unmet needs for Gender Dysphoria

DelveInsight's 'Gender Dysphoria - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gender Dysphoria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Gender Dysphoria: Understanding

DelveInsight's gender dysphoria epidemiology report gives a thorough understanding of the condition by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for gender dysphoria in the US, Europe, and Japan. Moreover, the report covers detailed information on the gender dysphoria epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight:

This section encompassing gender dysphoria epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The gender dysphoria epidemiology data are studied through all possible divisions to understand the Disease scenario in 7MM better. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The gender dysphoria epidemiology covered in the report provides historical and forecasted epidemiology scenarios in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

The gender dysphoria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns

  • The gender dysphoria report and model provide an overview of the global trends of gender dysphoria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of gender dysphoria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of gender dysphoria.
  • The report provides the segmentation of the gender dysphoria epidemiology

Report Highlights::

  • 11-year Forecast of Gender Dysphoria Epidemiology
  • 7MM Coverage
  • Prevalence of gender dysphoria
  • Gender-specific prevalence of gender dysphoria
  • Comorbidities associated with gender dysphoria

KOL - Views:

We interview KOLs and include SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to gender dysphoria?
  • What are the key findings pertaining to the Gender Dysphoria epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of gender dysphoria patients across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of gender dysphoria?
  • What are the currently available treatments of gender dysphoria?

Reasons to buy:

The Gender Dysphoria Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Gender Dysphoria market.
  • Quantify patient populations in the global gender dysphoria market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gender Dysphoria therapeutics in each of the markets covered.
  • Understand the magnitude of gender dysphoria population by its epidemiology.
  • The gender dysphoria epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments:

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1 Key Insights

2 Executive Summary of Gender Dysphoria

3 SWOT Analysis for Gender Dysphoria

4 Gender Dysphoria Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Gender Dysphoria in 2017
  • 4.2 Market Share (%) Distribution of Gender Dysphoria in 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Definitions
  • 5.3 Etiology
  • 5.4 Gender identity and Development of Gender Dysphoria
  • 5.5 Pathophysiology
  • 5.6 Diagnosis

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Total Prevalent Population of Gender Dysphoria
  • 6.3 Assumptions and Rationale - 7MM

7 Country-wise epidemiology of Gender Dysphoria

  • 7.1 The United States
    • 7.1.1 Prevalence of Gender Dysphoria in the United States
    • 7.1.2 Gender-specific Prevalence of Gender Dysphoria in the United States
    • 7.1.3 Comorbidities Associated with Gender Dysphoria in the United States
  • 7.2 Germany
    • 7.2.1 Prevalence of Gender Dysphoria in Germany
    • 7.2.2 Gender-specific Prevalence of Gender Dysphoria in Germany
    • 7.2.3 Comorbidities Associated with Gender Dysphoria in Germany
  • 7.3 France
    • 7.3.1 Prevalence of Gender Dysphoria in France
    • 7.3.2 Gender-specific Prevalence of Gender Dysphoria in France
    • 7.3.3 Comorbidities Associated with Gender Dysphoria in France
  • 7.4 Italy
    • 7.4.1 Prevalence of Gender Dysphoria in Italy
    • 7.4.2 Gender-specific Prevalence of Gender Dysphoria in Italy
    • 7.4.3 Comorbidities Associated with Gender Dysphoria in Italy
  • 7.5 Spain
    • 7.5.1 Prevalence of Gender Dysphoria in Spain
    • 7.5.2 Gender-specific Prevalence of Gender Dysphoria in Spain
    • 7.5.3 Comorbidities Associated with Gender Dysphoria in Spain
  • 7.6 United Kingdom
    • 7.6.1 Prevalence of Gender Dysphoria in the United Kingdom
    • 7.6.2 Gender-specific Prevalence of Gender Dysphoria in the United Kingdom
    • 7.6.3 Comorbidities Associated with Gender Dysphoria in the United Kingdom
  • 7.7 Japan
    • 7.7.1 Diagnosed Prevalence of Gender Dysphoria in Japan
    • 7.7.2 Gender-specific Prevalence of Gender Dysphoria in Japan
    • 7.7.3 Comorbidities Associated with Gender Dysphoria in Japan

8 Treatment

  • 8.1 Guidelines

World Professional Association for Transgender Health (WPATH) Guidelines

Endocrine Society Guidelines

  • 8.2 Patient journey
  • 8.3 Case Study

Title: Transgender Care in the Primary Care Setting

  • 8.4 Access to healthcare services, insurance coverage and its impact on Trans people
  • 8.5 Discrimination, social stigma, and other social issues

9 Unmet Needs

10 Appendix

  • 10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

Back to Top
전화 문의
F A Q